An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
Status:
Enrolling by invitation
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study of IMR-687 in adult patients who completed Imara's
blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term
safety and tolerability.